



For immediate release – July 1, 2008

VETOQUINOL STRENGTHENS ITS PRESENCE IN CANADA IN THE COMPANION ANIMAL MARKET

Lure, France – July 1, 2008 – Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC.

The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada.

The assets transferred in the deal are a portfolio of ophthalmological products, some non-sterile products that will be manufactured by the production unit of Vétoquinol located in Princeville, Canada. The products that were sold include the market clearances related to them.

Number three in Canada, Vétoquinol is today firmly established in the livestock market, which accounts for the majority of its revenue. This acquisition in the companion animal segment contributes to building the group's strategy of maintaining a balance between species.

"These anti-infectious ophthalmological products, which are top-of-market and technical, are a very good fit with our current range. They will be added to the portfolio of our dedicated companion animal sales force in Canada," said Etienne FRECHIN, Chairman and CEO of the Vétoquinol group.

Upcoming events: 2008 half-year revenues (July 22, 2008)

About Vétoquinol S.A.

Vétoquinol, established in 1933, is an independent veterinary pharmaceutical laboratory for both food producing animals and pets. This family-owned Group, dedicated to animal health, is the world's 12th largest laboratory in its field. Nearly 80% of its revenue is now generated in export markets.

Its business includes research, production and marketing of drugs and health products. Vétoquinol, positioned in the treatment field, has extensive expertise in 3 major therapeutic fields: anti-infection agents, pain and inflammatory, and cardiology-nephrology.

The Group now distributes its products in about one hundred countries (Europe, North America and Asia), working through 18 subsidiaries and a network of 110 distributor-partners. The company had more than 1,300 employees worldwide and Vétoquinol earned revenue of €233.4 million in 2007.

More information: www.vetoquinol.com

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For further information, contact

VETOQUINOL

Finance Department
Pierre KONAREFF
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor Relations
Emmanuel DOVERGNE
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

Media Relations

Alix HÉRIARD DUBREUIL
Tel.: +33 (0)1 56 43 44 62
alix.heriard@keima.fr